Sanofi US
Cambridge
Massachusetts
United States
230 articles about Sanofi US
-
French healthcare and pharma company Sanofi will terminate an undisclosed number of positions in its U.S. vaccines commercial unit in an effort to streamline the strategic sales structure.
-
IGM Biosciences Announces Refocusing of Sanofi Collaboration
4/17/2024
IGM Biosciences, Inc. today announced that the Company’s exclusive worldwide collaboration agreement with Sanofi to create and develop IgM agonist antibodies will now focus exclusively on immunology/inflammation targets.
-
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6
4/9/2024
Nurix Therapeutics, Inc. announced today an extension of the ongoing research program with Sanofi for STAT6 (signal transducer and activator of transcription 6).
-
Sanofi has in principle reached a settlement related to its discontinued heartburn drug Zantac, though the French pharma did not disclose the financial terms of the deal.
-
AstraZeneca and Sanofi’s respiratory syncytial virus immunizing antibody Beyfortus reached effectiveness of 90% against infection-related hospitalization in infants, according to the Centers for Disease Control and Prevention.
-
From entering college in China at just 15 to co-inventing a drug for Bayer, Mei’s career journey has been far from average. Now CMO at Editas, he’s not done yet.
-
The FDA’s target decision date is June 27, 2024, the companies announced Friday. Sanofi and Regeneron are looking to expand blockbuster Dupixent into chronic obstructive pulmonary disease.
-
In a Phase II study, Sanofi and Denali’s RIPK1 inhibitor SAR443820/DNL788 failed to meet the primary endpoint of improved functional performance in amyotrophic lateral sclerosis patients.
-
The French drugmaker Thursday touted trial results in The New England Journal of Medicine showing frexalimab significantly slowed disease activity in people with relapsing multiple sclerosis.
-
Graviton Bioscience Announces Strategic Investment from Sanofi to Advance Development of the Next Generation of Selective ROCK2 Inhibitors
2/1/2024
Graviton Bioscience along with other therapeutic compounds, announces a strategic investment from Sanofi.
-
Despite strong sales of its blockbuster drug Dupixent, Sanofi on Thursday reported that its fourth-quarter 2023 operating income dropped 5% due to a weaker U.S. dollar, high expenses and generic competition.
-
Synthekine Announces Strategic Collaboration with Sanofi to Develop Selective IL-10 Agonists for Treatment of Inflammatory Diseases
1/29/2024
Synthekine to receive $40 million upfront payment and eligible to receive milestones, in addition to tiered royalties on net sales.
-
With the FDA’s approval on Thursday, Dupixent can now be used for the treatment of children aged 1 to 11 years who have eosinophilic esophagitis, a chronic disease that can severely impact their ability to eat.
-
The French drugmaker is buying California-based biotech Inhibrx to gain access to its clinical-stage drug candidate for alpha-1 antitrypsin deficiency, as it tries winning over investors with potential blockbusters.
-
From ALS to depression to Huntington’s disease, many neuroscience-focused companies are anticipating key data over the next few months.
-
Amid the Biden administration’s efforts to reduce drug prices, Reuters reported in an exclusive that several pharmaceutical companies will raise pharma prices in January 2024.
-
The company is ending its program evaluating antibody-drug conjugate tusamitamab ravtansine after a non-small cell lung cancer trial did not meet a primary endpoint.
-
At the urging of the Biden administration, Sanofi and AstraZeneca are pledging 230,000 additional doses of their respiratory syncytial virus infant immunization Beyfortus in January 2024.
-
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
11/30/2023
Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today closing of its collaboration deal to co-develop and co-commercialize asset TEV ‘574 with Sanofi (EURONEXT: SAN and NASDAQ: SNY).
-
The FDA is gearing up for six decisions in the next two weeks, two of which involve highly anticipated medicines for rare diseases.